Abstract

Imaging by fluorodeoxyglucose positron-emission tomography (pet) has emerged as a valuable tool in the management of locally advanced cervical cancer (lacc), both for assessment of lymph node status and determination of response to chemoradiotherapy. The aim of the present study was to survey Canadian radiation oncologists to determine access to pet imaging for lacc patients and to assess current patterns of practice. Radiation oncology centres across Canada were contacted to identify radiation oncologists who treat patients with lacc. The focus of the survey was patients treated with radical chemoradiotherapy with curative intent. An anonymous online tool was used to distribute a 23-item questionnaire asking about access to pet imaging, opinions on indications for pet imaging, and practice patterns relating to the use of pet in this patient population. Questionnaire responses were tabulated and analyzed. The response rate was 65% (35 of 54 questionnaire recipients). Most respondents (80%) have access to pet for lacc patients, usually restricted to study protocols. Of the respondents,48% considered that access to pet was timely. Frequency of routine orders for pet before and after treatment (to assess response) was 63% and 15% respectively. With better access, 91% of respondents would routinely order pet before treatment, and 61% would routinely order it for posttreatment assessment. For initial staging, 85% of respondents considered pet to be a standard of care, and nearly half (45%) believed it should be a standard of care to assess treatment response. Because of access limitations, nearly 70% of respondents (23 of 34) do not order pet as often as they feel it is clinically indicated, and 74% agree that better access to pet would lead to improved care for lacc patients in Canada. Canadian radiation oncologists support the routine use of pet imaging in the initial workup of patients with lacc. Access to pet imaging limits routine use for these patients in clinically indicated situations. There is strong support for developing guidelines for pet use in this patient population.

Highlights

  • Imaging by fluorodeoxyglucose positron-emission tomography has emerged as a valuable tool in the clinical management of cervical cancer

  • Nearly 70% of respondents (23 of 34) do not order pet as often as they feel it is clinically indicated, and 74% agree that better access to pet would lead to improved care for lacc patients in Canada

  • Canadian radiation oncologists support the routine use of pet imaging in the initial workup of patients with lacc

Read more

Summary

Introduction

Imaging by fluorodeoxyglucose positron-emission tomography (pet) has emerged as a valuable tool in the clinical management of cervical cancer. For patients with locally advanced cervical cancer (lacc), pet imaging performed as part of the pre-treatment staging workup is highly sensitive and specific for detecting lymph node metastases, and is thereby strongly prognostic for survival[1]. Imaging by pet may significantly alter the initial management approach for cervical cancer patients. A recent single-centre prospective cohort study investigated the use of pet to assess treatment response and found that the results of pet imaging 3 months post-therapy were highly predictive of survival[3]. The role of pet imaging in routine follow-up, detection of recurrence, and salvage therapy guidance for cervical cancer patients remains investigational[5,6,7]

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.